Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Organ Preservation Trial Using Cetuximab and Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to One Cycle of Induction Chemotherapy With Taxotere, Cisplatin, 5-Fluorouracil (TPF), and Cetuximab

NCT00599131 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT00599131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00599131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Organ Preservation Trial Using Cetuximab and Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to One Cycle of Induction Chemotherapy With Taxotere, Cisplatin, 5-Fluorouracil (TPF), and Cetuximab
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2007
Completion date
October 31, 2010
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of larynx